VXRT - Vaxart, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Vaxart, Inc.

395 Oyster Point Boulevard
Suite 405
South San Francisco, CA 94080
United States

Full Time Employees28

Key Executives

NameTitlePayExercisedYear Born
Dr. Wouter W. Latour M.B.A., M.D., MBAPres, CEO, CFO & Director458.25kN/A1958
Dr. Sean N. TuckerFounder & Chief Scientific Officer327.61kN/A1968
Mr. John M. Harland M.B.A., CPAConsultant353.25kN/A1952
Ms. Margaret A. EcherdVP, Corp. Controller & Principal Accounting OfficerN/AN/A1959
Mr. Brant BiehnSr. VP of Commercial OperationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Vaxart, Inc., a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.

Corporate Governance

Vaxart, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.